Business profile & competitive position
Becton, Dickinson and Company (BDX) is a global medical-technology company classified in the Healthcare sector, specifically the Medical - Instruments & Supplies industry. As described in its most recent 10-K, BD develops, manufactures and sells a broad set of medical supplies, devices, laboratory equipment and diagnostic products used by hospitals, physicians, clinical laboratories, pharmaceutical companies, researchers and consumers. Its portfolio spans medication management, infection prevention, surgical and interventional devices, drug delivery, anesthesiology, infectious-disease and cancer diagnostics, and cellular research tools. As of September 30, 2025, the company operated through three worldwide segments: BD Medical, BD Life Sciences and BD Interventional.
The financial profile, however, suggests a business whose profitability is solid but not towering. The trailing net margin is 5.7% and return on equity is 3.7%, figures that are positive but relatively modest for a company often perceived as a diversified healthcare stalwart. Those numbers imply BD earns reliable recurring revenue, but its competitive moat is not currently generating outsized returns; scale, regulation and long-standing customer relationships appear to provide stability more than extraordinary pricing power. Investors should look at these margins and ROE as evidence that BD is a large, defensive operator rather than a high-margin device innovator.
Financial posture
BDX carries a market capitalization of $58.6 billion and trades at a price-to-earnings ratio of 51.9. Against a 5.7% net margin and 3.7% ROE, that P/E is quite high. It means the market is pricing in significant future improvement—likely tied to the company’s restructuring, portfolio reshaping and integration of recent acquisitions—rather than rewarding the current level of earnings alone. The beta of 0.28 confirms the stock behaves defensively relative to the broader equity market, consistent with a non-discretionary healthcare supplier whose revenues are largely insulated from economic cycles.
On a technical snapshot as of November 10, 2026, the stock closed at $215.25 with a 50-day exponential moving average of $190.38 and an RSI of 76.9. The distance between the current price and the 50-day EMA, plus the RSI above 70, suggests the shares have moved sharply in the short term. None of this implies where the stock should go next, but it does frame the valuation: a low-volatility healthcare name trading at a premium multiple and a technically stretched short-term condition.
Strategic priorities & outlook
BD’s 10-K outlines a company in the middle of a portfolio transformation rather than a steady-state operation. Effective October 1, 2025, BD reorganized into five separately-managed segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences. This reorganization is the backdrop against which near-term execution should be judged; management is realigning reporting and resources around product categories it believes offer clearer strategic focus.
The most significant pending transaction is the Reverse Morris Trust combination of BD’s Biosciences and Diagnostic Solutions business with Waters Corporation, expected to close around the end of the first quarter of calendar 2026. BD expects to receive roughly $4 billion in cash at closing and for its shareholders to own approximately 39.2% of the combined entity. That is a material change in composition and balance-sheet capacity. At the same time, BD is integrating the $3.914 billion acquisition of Edwards Lifesciences’ Critical Care product group, which closed in September 2024 and is now housed as BD Advanced Patient Monitoring within BD Medical.
Portfolio cleanup is also part of the story. BD divested its Diabetes Care business (Embecta Corp.) in April 2022 and sold the Interventional segment’s Surgical Instrumentation platform in August 2023, booking a pre-tax gain of about $268 million. Manufacturing is spread across 18 countries outside the United States, spanning EMEA, Greater Asia, Latin America and Canada, which introduces foreign-exchange and foreign-economic considerations the company explicitly flags as riskier than domestic operations.
Macro & geopolitical exposure
As a Medical - Instruments & Supplies company, BDX sits at the intersection of healthcare policy, regulation, global trade and currency markets. The industry is heavily governed by FDA and equivalent foreign regulators, so product approvals, quality inspections, recalls and Good Manufacturing Practice standards are ongoing operational realities. Reimbursement decisions by Medicare, Medicaid and private payers also influence adoption of devices and diagnostics, even when demand is clinically driven.
Because BD manufactures in 18 countries and sells globally, it is exposed to exchange-rate swings, tariffs and cross-border shipping costs. Medical-device supply chains rely on specialized plastics, resins, metals and sterile packaging, making input-cost inflation and logistics constraints relevant over time. In addition, sterilization regulations and environmental standards have tightened in parts of the world, adding compliance costs to the sector. While demand for many BD products is non-discretionary, the revenue and margin profile can still fluctuate with macro factors rather than solely with volume growth.
Recent developments
Over the first week of November 2026, the public news flow around BDX has been dominated by dividend-related coverage rather than product or M&A announcements:
- November 8, 2026 — Dividend Announcements: October 31-November 6, 2026 (Part 1 Of 2) (seekingalpha.com)
- November 7, 2026 — 3 Medical Device Stocks That Keep Raising Dividends. One Just Hit 55 Years (247wallst.com)
- November 6, 2026 — Dividend Champion, Contender, And Challenger Highlights: Week of November 8 (seekingalpha.com)
- November 6, 2026 — 3 Stocks in Focus That Hiked Dividends Amid Ongoing Market Volatility (zacks.com)
The 247wallst.com headline explicitly highlights BD’s 55-year record of dividend increases, a streak that underlines management’s cash-flow discipline and the stock’s income-investor appeal. None of the recent headlines addressed earnings-relevant operational shifts, so the dividend story remains the dominant near-term narrative in public financial media.
Earnings behavior & post-earnings drift
BDX has produced a strong earnings track record over the last eight reported quarters, beating consensus estimates every time, for a beat rate of 8/8 (100%). The average earnings surprise across those eight quarters is 8.3%. The average five-trading-day price move following those reports is +1.94%, classified as an upward post-earnings drift.
Looking at the four most recent quarters:
- November 5, 2026: EPS of $4.15 versus an estimate of $4.07, a 2.0% beat. The stock fell 0.78% the next day and was flat (0%) over the following five sessions.
- August 6, 2026: EPS of $3.23 versus an estimate of $3.14, a 2.9% beat. The stock dipped 0.12% the next day but rose 2.77% over the following five sessions.
- May 7, 2026: EPS of $2.90 versus an estimate of $2.78, a 4.3% beat. The stock dropped 2.5% the next day and declined 5.74% over the following five sessions.
- February 9, 2026: EPS of $2.91 versus an estimate of $2.21, a 31.7% beat. The stock rallied 5.3% the next day and 8.8% over the following five sessions.
The pattern shows that beating estimates has not guaranteed a positive immediate reaction; both the May and November 2026 beats were followed by short-term selling. The strongest post-earnings response was tied to the outsized February 2026 surprise, while smaller beats have produced more muted or negative price action. BD is next scheduled to report on February 8, 2027 before the market open, with the current consensus EPS estimate at $2.71. Traders should note that the company’s strong beat history does not remove the risk of a “sell the news” response if results merely clear a lowered bar or if guidance disappoints.
For a deeper dive into how institutional analysts are interpreting BD’s valuation, restructuring progress and next earnings setup, consider reviewing the full institutional verdict on the ticker page.
Frequently Asked Questions
What does Becton, Dickinson and Company actually do?
BDX is a global medical technology company that develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products. Its customers include healthcare institutions, physicians, clinical labs, pharmaceutical companies, life-science researchers and consumers. As of September 30, 2025, its three segments were BD Medical, BD Life Sciences and BD Interventional.
How strong has BD's recent earnings performance been?
Over the last eight reported quarters, BD has beaten consensus EPS estimates 100% of the time, with an average earnings surprise of 8.3% and an average five-day post-earnings price move of +1.94%. The February 2026 quarter was the standout, with a 31.7% surprise and a five-day gain of 8.8%.
What are BD's main strategic priorities right now?
BD’s priorities include completing the Reverse Morris Trust combination of its Biosciences and Diagnostic Solutions business with Waters Corporation, integrating the $3.914 billion acquisition of Edwards Lifesciences’ Critical Care group, and executing an October 2025 reorganization into five separately-managed segments. The Waters deal is expected to bring roughly $4 billion in cash and leave BD shareholders with about 39.2% of the combined company.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-11-05 | $4.15 | $4.07 | +2% | -0.78% | null% |
| 2026-08-06 | $3.23 | $3.14 | +2.9% | -0.12% | +2.77% |
| 2026-05-07 | $2.9 | $2.78 | +4.3% | -2.5% | -5.74% |
| 2026-02-09 | $2.91 | $2.21 | +31.7% | +5.3% | +8.8% |
| 2025-11-06 | $3.96 | $3.92 | +1% | - | - |
| 2025-08-07 | $3.68 | $3.4 | +8.2% | - | - |
Previous BDX editions
Get the institutional verdict on BDX
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the BDX verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.